Jim Cramer in a column Tuesday took a closer look at the changes on the Dow Jones industrial average. One change was that Amgen (AMGN) is replacing Pfizer (PFE) . Cramer said this move makes perfect sense, as all of the growth, innovation and excitement now comes from biotech. It hasn't come from big pharma in many years, he said, and while there are other names he would have chosen, Amgen is a fine representative of its sector.
More from Investing
A break in a key support level could precipitate further declines in the life sciences company's shares.
Smaller to mid-cap names have fared somewhat better than large cap tech, but make no mistake... there is a circle of life/death here.
Investing can be fun until it turns brutal for what seems to be no reason.
Dip buyers have lost confidence as selling momentum builds.